PDF(Pubmed)
Abstract：
UNASSIGNED: Vaginal cancer is a rare gynecologic malignancy. While in a localized disease, concurrent chemoradiation grants local control and better overall survival, in a metastatic setting, the management options are very limited. Furthermore, recurrent cervical, vulvar, and vaginal carcinomas notoriously develop resistance to treatment, and consequently, their prognosis is still poor.
UNASSIGNED: We herein present the case of a woman with a nodal relapse of vaginal carcinoma, effectively treated with third-line immunotherapy. We will also provide a review of the literature on the new therapeutic strategies for advanced vaginal carcinoma, with a focus on pembrolizumab immunotherapy.
UNASSIGNED: Pembrolizumab might represent a promising option for the management of vaginal and vulvar cancer, but data to support its use in this setting are still lacking. This case highlights the need for further investigation and trial designs for this rare disease.
UNASSIGNED: We herein present the case of a woman with a nodal relapse of vaginal carcinoma, effectively treated with third-line immunotherapy. We will also provide a review of the literature on the new therapeutic strategies for advanced vaginal carcinoma, with a focus on pembrolizumab immunotherapy.
UNASSIGNED: Pembrolizumab might represent a promising option for the management of vaginal and vulvar cancer, but data to support its use in this setting are still lacking. This case highlights the need for further investigation and trial designs for this rare disease.
摘要：
■阴道癌是一种罕见的妇科恶性肿瘤。在局部疾病中，同步放化疗给予局部控制和更好的总体生存率，在转移性环境中，管理选择非常有限。此外，复发性宫颈，外阴,众所周知，阴道癌对治疗产生抗药性，因此，他们的预后仍然很差。
■我们在此介绍一个女性阴道癌淋巴结复发的病例，用三线免疫疗法有效治疗。我们还将提供有关晚期阴道癌的新治疗策略的文献综述，专注于pembrolizumab免疫疗法。
■Pembrolizumab可能是治疗阴道癌和外阴癌的一种有希望的选择，但是仍然缺乏支持其在此设置中使用的数据。该病例强调了对这种罕见疾病进行进一步调查和试验设计的必要性。
■我们在此介绍一个女性阴道癌淋巴结复发的病例，用三线免疫疗法有效治疗。我们还将提供有关晚期阴道癌的新治疗策略的文献综述，专注于pembrolizumab免疫疗法。
■Pembrolizumab可能是治疗阴道癌和外阴癌的一种有希望的选择，但是仍然缺乏支持其在此设置中使用的数据。该病例强调了对这种罕见疾病进行进一步调查和试验设计的必要性。
